Potent and prolonged-acting cyclic lactam analogs of .alpha.-melanotropin: design based on molecular dynamics
- 1 December 1989
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 32 (12), 2555-2561
- https://doi.org/10.1021/jm00132a010
Abstract
Utilizing results from previous structure-activity relationships and theoretical studies of .alpha.-melanotropin (.alpha.-MSH, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and its related superpotent analogues, Ac-[Nle4,d-Phe7]-.alpha.-MSH and Ac-[Cys4,Cys10]-.alpha.-MSH, we have designed a new class of .alpha.-MSH4-13 and .alpha.-MSH4-10 cyclic lactam fragment analogues of .alpha.-melanotropin. The cyclic peptides have the following general structures: Ac-[Nel4,Xxx5,D-Phe7, Yyy10Gly11]-.alpha.-MSH4-13-NH2 and Ac[Nle4,Xxx5,D-Phe7,Yyy10]-.alpha.-MSH4-10-NH2, where Xxx = Glu or Asp and Yyy = Lys, Orn, Dab, or Dpr. Formation of the lactam bridge between the side-chain groups Xxx and Yyy was performed either in solution or on a solid-phase support. Seven cyclic peptides were prepared and bioassayed for their melanotropic potency by using standard frog (Rana pipiens) and lizard (Anolis carolinensis) skin bioassays. Relative to .alpha.-MSH (relative potency = 1), the potencies of the cyclic peptides in the lizard skin bioassay were as follows: .alpha.-MSH (1); Ac-[Nle4,Glu5,D-Phe7,Lys10,Gly11]-.alpha.-MSH4-13-NH2 (6); Ac-[Nle4,Asp5,D-Phe7,Lys10,Gly11]-.alpha.-MSH4-13-NH2 (100); Ac-[Nle4,Glu5,D-Phe7,Lys10]-.alpha.-MSH4-10-NH2 (9); Ac-[Nle4,Asp5,D-Phe7,Lys10]-.alpha.-MSH4-10-NH2 (90); Ac-[Nle4,Asp5,D-Phe7,Orn10]-.alpha.-MSH4-10-NH2 (20); Ac-[Nle4,Asp5,D-Phe7,Dab10]-.alpha.-MSH4-10-NH2 (5); Ac-[Nel4,Asp5,D-Phe7,Dpr10]-.alpha.-MSH4-10-NH2 (5). Similar results were obtained in the frog skin bioassay, but the analogues were much less potent. Cyclic melanotropins with 23-membered rings exhibited 100-fold higher malanotropic potency than .alpha.-MSH with selectivity for the lizard melanocyte receptors over the frog melanocyte receptors. Increasing or decreasing the ring size of these cyclic melanotropins from 23 diminishes the biological potency of the resulting cyclic peptide. The 23- and 24-membered ring analogues showed prolonged (residual) biological activities in both biological assays, but the smaller ring systems (20, 21, 22) did not. These results provide new insights into the structural and conformational requirements of .alpha.-MSH and its analogues at two different types of pigment cell (melanocyte) receptors.This publication has 14 references indexed in Scilit:
- Relative stability of α-melanotropin and related analogues to rat brain homogenatesPeptides, 1984
- Cyclic melanotropins. 5. Importance of the C-terminal tripeptide (Lys-Pro-Val)Journal of Medicinal Chemistry, 1984
- Melanotropin bioassays: In vitro and in vivo comparisonsGeneral and Comparative Endocrinology, 1984
- Enzymological studies of melanotropinsComparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1984
- Structure-activity studies of highly potent cyclic [Cys4, Cys10]melanotropin analogsJournal of Medicinal Chemistry, 1983
- [half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity.Proceedings of the National Academy of Sciences, 1982
- DEPROTECTION OF NIN-FORMYL TRYPTOPHAN USING 1,2-ETHANEDITHIOL IN LIQUID-HYDROGEN FLUORIDE1982
- Calcium-Dependent Prolonged Effects on Melanophores of [4-Norleucine, 7-D-Phenylalanine]-α-MelanotropinScience, 1981
- 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.Proceedings of the National Academy of Sciences, 1980
- IN VITROBIOASSAY FOR THE MELANOCYTE STIMULATING HORMONE1Endocrinology, 1954